Rare Diseases

The new (provisional) 2025 EULAR/ACR classification criteria for anti-synthetase syndrome #EULAR2025 @RheumNow https://t.co/X6VjcN8XZe

Links:

David Liew @drdavidliew( View Tweet )
#EULAR2025 Abstr#OP0202 Phase 1/2 of Resel-cel, a 4-1BB-containing human CD19-CAR T cell (weight-based 1 x infusion) reported efficacy in 8 patients (#SLE and LN) at WK28. 2 x Grade 1 CRS & 1 x Grade 4 ICANS. 1 x HLH, not attributed to SLE flare. Need longterm data @RheumNow https://t.co/COCKlqw687

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#WIN in systemic sclerosis (SSc): -Ongoing trials now targeting multiple pathways. -CONQUEST platform may reshape research in Ssc and other autoimmune diseases. -Revised CRISS could replace single organ endpoints for approval. #EULAR2025 @RheumNow https://t.co/kxSeFb5lAU

Links:

Adela Castro @AdelaCastro222( View Tweet )
What ‘CAR’ to drive? #CAR-T buzz was at #EULAR2025 In multiple #rheumatic #diseases #SLE #Scleroderma #Sjogrens #myositis Even #axial #SpA Who - active, not a lot of damage Which target 🎯 Which priming regiment What will results be compared to? Who will pay? @RheumNow

Janet Pope @Janetbirdope( View Tweet )

#CAR-T in active #scleroderma #diffuse open label @sclerodermaUM presented improvement in #nailfold #capillary patterns Suggesting #vascular recovery Hope is for lungs, skin and survival to improve but These are ▶️ Early days ?risk OP0338 #EULAR2025. @RheumNow @eular_org https://t.co/QhmO6gekXk

Links:

Janet Pope @Janetbirdope( View Tweet )
Despite the evolution of anti-synthetase antibodies, there’s a clear need for better ways to define the disease. Enter the ACR/EULAR CLASS initiative - classification criteria for anti-synthetase syndrome ⬇️ see the next tweet #EULAR2025 @RheumNow https://t.co/Z3rPOt1vlx

Links:

David Liew @drdavidliew( View Tweet )
EULAR/ACR Classification Criteria for #ASyS, the new acronym of Antisynthetase Syndrome 🔺️Do not apply if patient is positive for other antibodies like SSA #EULAR2025 @RheumNow https://t.co/AD5tTipBtt

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
Joint pain and fatigue are actually the biggest issues for people living with haemochromatosis, but we in rheumatology don’t have organized care for them. A call to action from Patrick Kiely, to do better by these patients #EULAR2025 @RheumNow https://t.co/h3Zvov642L

Links:

David Liew @drdavidliew( View Tweet )
Manifestations of relapsing polychondritis @Lupusreference @RheumNow #EULAR2025 https://t.co/EuPOdKKjax

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#Relapsing_Polychondritis Main differential diagnosis is GPA 🔺️No ANCA and no renal involvement in relapsing polychondritis @Lupusreference #EULAR2025 @RheumNow https://t.co/QUJZ3EDjj3

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
FIBRONEER-ILD Ph3 PD4B inhibitor Nerandomilast 1100+ pts, 320+ w/ SARD-ILD wk52 FVC relative reduction of decline 9 mg bid 43% 18 mg bid 39% vs. PBO HR 0.56 time to first acute exacerbation of ILD, hospitalisation for resp cause or death in higher dose group 11% https://t.co/CeXWB2GlOe

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Migrant health literacy challenges - Individual interviews with participants with rheumatic diseases (interpreters used) multiple aspects - Individual, Providers and system level Navigating health care systems #EULAR2025 @RheumNow https://t.co/cWQ6jP8RZe

Links:

Bella Mehta @bella_mehta( View Tweet )
Great talk by @Lupusreference on Relapsing Polychondritis and a highlight of #EULAR2025. Do not forget about the articular presentations of relapsing polychondritis @RheumNow https://t.co/1xZY7VkX1z

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
"H Syndrome" review of 23 French pts. Autoinflammatory dz due to variants of SLC29A3 gene. Multisystem histiocytic lymphoproliferative disorder of young adults- skin 2/3, sensorineural hearing loss, fever w/ endo & autoimmune dz. Best responses w IL6 inhib. #EULAR2025 Abst https://t.co/F7NGI4TkJS
Dr. John Cush @RheumNow( View Tweet )
#EULAR2025 Abstr#OP0319 Multicentre study in Canada showed no difference in longterm Lung Transplant outcomes among IIM-ILD, SSc-ILD & IPF. Some differences: IIM-ILD was progressive pre-transplant with prolonged hospitalisation post-surgery. For us to be aware @RheumNow https://t.co/eFdY4XGtlj

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
pssfing.jpg

Predictors and Outcomes in Systemic Sclerosis

EurekAlert!

The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.

Read Article
SLE Preview: advances to achieve deep B-cell depletion The race is on for the first chimeric antigen receptor (CAR)-based therapy to be approved for the treatment of systemic lupus erythematosus (SLE). Its main principle is to induce deep B-cell depletion, with the hope to reset https://t.co/OzQ05YFZfb
Dr. John Cush @RheumNow( View Tweet )
EULAR,poster

EULAR 2025 – Day 2 Report

Jack Cush, MD

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few

Read Article
Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies #EULAR2025 @RheumNow l https://t.co/5bbQnHV6CI

Links:

David Liew @drdavidliew( View Tweet )
Age of onset is really important when thinking about #MAS Primary HLH more frequent in pediatric population. But can continue to adulthood. #EULAR2025 @RheumNow https://t.co/J7xmTiQiwr

Links:

Bella Mehta @bella_mehta( View Tweet )
MAS can be triggered by infections in VEXAS syndrome. The threshold is reached leading to a hyperinflammatory state Georgin-Lavialle S @rheumnow #EULAR2025 https://t.co/NKLL75rOgP

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
3 Fs of diagnosis of #HLH -Fever -Ferritin -Falling blood count Raising awareness is the key! Especially in rare diseases like this where the morbidity and mortality is super high! Collaboration between specialists help HLH networks will be helpful like this @RheumNow #EULAR2025 https://t.co/HWbvIma3yx

Links:

Bella Mehta @bella_mehta( View Tweet )
Treatment strategies for steroid free management of #relapsingpolychondritis 56 patients from a single center #POS0149 #EULAR2025 @RheumNow https://t.co/d4I56opS02

Links:

Bella Mehta @bella_mehta( View Tweet )
#MITIGATE subgroup analysis: Inebilizumab reduced flares & boosted remission across all #IgG4-RD subgroups. HR for flare vs PBO: 0.12-0.16 across sex/race. Similar results for all subgroups in achieving flare-free, treatment-free complete remission. @RheumNow #EULAR2025 #OP0189

Mrinalini Dey @DrMiniDey( View Tweet )

RA-related premature mortality highest in American Indians--> 3.6x odds of death in <65 vs White peers, w/ no improvement over 22 yrs. COVID widened the gap. Need to address structural & social drivers of early death in RA, & wider health disparities. @RheumNow #EULAR2025 #OP0197

Mrinalini Dey @DrMiniDey( View Tweet )

Recent Blogs

Choice Overload (and the Way Out)

Jack Cush, MD
paint,choice,overload,color
I recently overheard a very good practicing rheumatologist complain, “why do I need yet another drug for psoriatic arthritis? I have more treatment choices than I have actual PsA patients who need a new or better drug”. Read Post

Best of 2022: Five Mistakes When Diagnosing Still’s Disease

Jack Cush, MD
Thermometer
Adult-onset Still's presents an interesting and diagnostic challenge when encountered. Here are 5 tips to improve your diagnostic acumen for this febrile disorder. Read Post
×